Real-world data sheds light on next-step treatment for HER2+ breast cancer

This study looked at medical records of 86 people with HER2+ metastatic breast cancer to see how well a combination of three drugs (tucatinib, trastuzumab, and capecitabine) worked after they had already taken a drug called trastuzumab deruxtecan. The goal was to measure real-world outcomes like time until the next treatment or death. The study did not test a new treatment but instead gathered information from existing patient data to help doctors understand what happens next.